课题基金 / 基金详情

Pilot Project #2

Pilot Project #2
试点项目
批准号:
8849781
负责人:
Selvarangan Ponnazhagan
金额:
$4.48万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-23 至 2018-08-31

项目摘要

项目成果

Selvarangan Ponnazhagan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Prostate cancer (PCa) is the most common non-skin malignancy and the cancer second most responsible for death in men in United States. Prior studies with animal models of PCa and with humans demonstrated that the prostate produces various growth factors. Addition or blocking of these factors alters PCa cell proliferation and other functions. Among these factors, transforming growth factor-β1 (TGF-β) is involved in tumorigenicity, displays potent immunosuppressive activities, and is required for the conversion of conventional CD4+ T cells to FoxP3+ regulatory T (TR) cells. TR cells that express the transcription factor Foxp3 are essential for normal immune function; absence of TR cells results in multi-organ autoimmunity and death. A clear role of TGF-β and its effect on TR during PCa development and progression lacks experimental evidence. In this proposal, we plan to investigate the underlying mechanisms involved in the context of TGF-β and/or TR using PCa cell lines, derived from transgenic mouse for prostate cancer (TRAMP), in C57/B6 mice. Of these cell lines, TRAMP- C1 and TRAMP-C2 form tumors; TRAMP-C3 fails to do so. These mouse cell lines of PCa can be used to obtain the long-term goal of this project, which is to address the fundamental question: Do TR cells and/or TGF-β levels relate to differences in tumorigenicity of the TRAMP cell lines (C1, C2, and C3)? The objective of this project is to define the role of TGF-β production by host cells in response to or TGF-β expression by TRAMP cell lines and to establish the function of TGF-β on the conversion of naive CD4+ T cells into Foxp3-expressing TR cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer
  • 批准号:
    10586000
  • 项目类别:
  • 资助金额:
    $44.67万
  • 财政年份:
    2023
  • 负责人:
    Selvarangan Ponnazhagan
  • 依托单位:
Targeted therapy for breast cancer with osteolytic bone damage
Targeted therapy for breast cancer with osteolytic bone damage
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 项目类别:
    专项基金项目
  • 资助金额:
    12.0万元
  • 批准年份:
    2008
  • 负责人:
    焦宇飞
  • 依托单位: